Fairman Group’s Bristol-Myers Squibb BMY Stock Holding History

Fairman Group’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$44.8K	Hold	718	–	–	0.03%	105
2026 Q2	$41.4K	Hold	718	–	–	0.03%	110
2026 Q1	$43.5K	Hold	718	–	–	0.04%	102
2025 Q4	$38.7K	Hold	718	–	–	0.03%	111
2025 Q3	$32.4K	Hold	718	–	–	0.03%	120
2025 Q2	$33.2K	Sell	718 -101	-12%	-$4.96K	0.03%	115
2025 Q1	$46.3K	Hold	819	–	–	0.04%	99
2024 Q4	$46.3K	Hold	819	–	–	0.04%	109
2024 Q3	$42.4K	Hold	819	–	–	0.04%	117
2024 Q2	$34K	Hold	819	–	–	0.03%	127
2024 Q1	$44.4K	Hold	819	–	–	0.04%	105
2023 Q4	$42K	Buy	+819	New	+$43K	0.04%	114

Other funds holding BMY

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Pzena Investment Management New York $34.1B AUM 26.62% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

M&G plc London, United Kingdom $19.9B AUM 15.09% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57.1B AUM 43.46% 1-Year Est. Return

Fairman Group's BMY Position: Q3 2026 in Review

Fairman Group held its Bristol-Myers Squibb (BMY) position steady in Q3 2026 at 718 shares worth $44.8K. The position accounts for 0.03% of the portfolio, ranked #105.

Fairman Group first reported a position in BMY in Q4 2023 and has held it in 12 quarters since. The position peaked at $46.3K in Q1 2025. 1,350 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

Fairman Group held 718 shares of Bristol-Myers Squibb worth $44.8K as of Q3 2026.
Fairman Group left its Bristol-Myers Squibb share count unchanged in Q3 2026.
Bristol-Myers Squibb made up 0.03% of Fairman Group's portfolio in Q3 2026, its #105 holding.
Fairman Group first reported a position in Bristol-Myers Squibb in Q4 2023 and has held it in 12 quarters since.
Fairman Group's Bristol-Myers Squibb position peaked at $46.3K in Q1 2025.
1,350 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on Fairman Group's 13F filing for Q3 2026, filed 26 Oct 2026.